罗格列酮联合阿司匹林治疗对糖尿病代谢综合征患者胰岛素抵抗的影响

The effect of combination treatment of rosiglitazone and aspirin on insulin resistance in patients with diabetic metabolic syndrome

目的探讨罗格列酮(RGZ)联合阿司匹林(Asp)治疗对糖尿病代谢综合征(MS)患者胰岛素抵抗(IR)的影响。方法 126例MS患者按随机区组设计法分为基础治疗组(31例),Asp组(31例),RGZ组(32例),RGZ联合Asp组(32例),观察各组治疗前后FPG、2hPG、HbA_1 c、Ins、C-P、C-RP、纤维蛋白原水平及HOMA-IR等的变化。结果 RGZ联合Asp组FPG、2hPG、Ins、HOMA-IR、炎症因子水平均较其他三组下降。结论 RGZ联合Asp应用可协同改善糖尿病MS患者IR,并具有抗炎作用。

Objective To observe the effect of rosiglitazone combined with aspirin on insulin resistance in patients with diabetic metabolic syndrome. Methods Patients with diabetic metabolic syndrome （n= 126） were randomized into four groups. FPG, 2hPG, HbAlc, Fins, FC-P, C-RP, fibrinogen（Fib） levels and insulin resistance index by HOMA were assayed before and after the treatment. Results Levels of blood glucose, serum insulin, HOMA-IR and inflammatory factors were significantly improved in rosiglitazone plus aspirin group compared with isolated aspirin or rosiglitazone group and with control gruop. （all P〈0. 05）. Conclusions Rosiglitazone combined with aspirin plays a cooperation role in improving insulin resistance and exerts an anti- inflammatory effect in patients with diabetic metabolic syndrome.